EQS-Adhoc

LifeWatch AG: FDA clearance for continuous Vital Signs Monitoring Service

EQS Group-Ad-hoc: LifeWatch AG / Key word(s): Regulatory Approval
LifeWatch AG: FDA clearance for continuous Vital Signs Monitoring Service

09.02.2016 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

LifeWatch(TM) receives FDA clearance for its continuous Vital Signs
Monitoring Service

Zug/Switzerland, February 9, 2016 - LifeWatch AG (SIX Swiss Exchange:
LIFE), a leading developer and provider of medical solutions and remote
diagnostic monitoring services in the digital health market, is pleased to
announce that it has received FDA clearance for its continuous Vital Signs
Monitoring Service.

The wireless, patch-based vital signs monitoring system makes vital signs
monitoring faster, easier and more convenient for both, patients and
medical staff. It will allow for early detection of vital sign changes
thereby enabling faster interventions as well as increased nursing
efficiency and higher patient satisfaction.

The Vital Signs Patch is an easy-to-use cable-free sensor worn on a
patient's upper chest. It is intended to be used on adult patients in a
clinical environment for the continuous, non-invasive monitoring of ECG,
heart rate, respiration rate, surface temperature, arterial blood oxygen
saturation and body position. It will be available in two versions (with
and without ECG) and is connected with an easy-to-use wireless supporting
system, which provides medical information and alerts remotely to medical
staff. Although the system will initially be used in a medical facility
(hospital, nursing home, etc.), the even larger ambulatory market should
follow once the technology has been proven in the clinical environment.

Dr. Stephan Rietiker, CEO of LifeWatch, stated: "This clearance represents
another significant technological breakthrough for LifeWatch and further
strengthens our position as an innovational leader in digital health. I am
highly excited at the tremendous market potential for the easy-to-use Vital
Signs Patch, both in the clinical and ambulatory settings worldwide.
Furthermore, the cost benefits will allow vital signs monitoring to be
utilized for a much broader patient population. However, providing service
in a clinical environment is a new market for LifeWatch and will therefore
require both time and additional resources in order to ensure a successful
market launch."


For further questions:

LifeWatch AG
c/o Dynamics Group, Philippe Blangey / Doris Rudischhauser